September 18, 2014 6:30 AM ET

Pharmaceuticals

Company Overview of Urigen Pharmaceuticals, Inc.

Company Overview

Urigen Pharmaceuticals, Inc., a development stage company, engages in the development and commercialization of therapeutic products for patients with urological disorders in North America. Its clinical stage product includes URG101, a bladder instillation for bladder pain syndrome/intersticial cystitis for men and women. The company is based in Wilmington, Delaware.

501 Silverside Road

PMB #95

Wilmington, DE 19809

United States

2 Employees

Phone:

925-280-2861

Fax:

925-280-2861

Key Executives for Urigen Pharmaceuticals, Inc.

Chairman
Age: 50
Scientific Founder
Age: 70
Co-Founder and IP Counsel
Compensation as of Fiscal Year 2014.

Urigen Pharmaceuticals, Inc. Key Developments

Urigen Pharmaceuticals Raises $750,000 Debt Financing

Urigen Pharmaceuticals raised $750,000 in a debt financing, according to documents filed with the Securities & Exchange Commission. The Wilmington, Del., specialty pharmaceutical company specializes in the developing products for patients with urological ailments such as painful bladder syndrome, urethritis, nocturia and over active bladder. Urigen's lead new drug candidate, the experimental painful bladder syndrome treatment URG101, is a proprietary combination of approved drugs that is instilled into the bladder. The company was seeking to raise $1 million.

SEC Revokes Registration Of Securities Of Urigen Pharmaceuticals

An Administrative Law Judge has issued an Initial Decision as to Urigen Pharmaceuticals, Inc. in Quintek Technologies, Inc., Admin. Proc. No. 3-14890. The Order Instituting Proceeding alleged that the company repeatedly failed to file required annual and quarterly reports while its securities were registered with the Securities and Exchange Commission (SEC). The Initial Decision finds these allegations to be true and revokes the registration of each class of registered securities of the company, pursuant to Section 12(j) of the Securities Exchange Act of 1934 (Exchange Act).

Similar Private Companies By Industry

Company Name Region
Extab Corporation United States
VSL Pharmaceuticals, Inc. United States
BiPar Sciences, Inc. United States
Perrigo Company United States
Nutra Med, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
May 27, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Urigen Pharmaceuticals, Inc., please visit www.urigen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.